WA
TECH icon

Winfield Associates’s Bio-Techne TECH Stock Holding History

Winfield Associates’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20
Closed -$1K – 594
2017
Q4 		$1K Hold
20
– – ﹤0.01% 789
2017
Q3 		$1K Sell
20
-120
-86% -$3.56K ﹤0.01% 726
2017
Q2 		$4K Buy
+140
New +$3.83K ﹤0.01% 590

Other funds holding TECH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Winfield Associates's TECH Position: Q1 2018 in Review

Winfield Associates sold out of Bio-Techne (TECH) in Q1 2018, closing a stake of 20 shares — an estimated $1K sold.

Winfield Associates first reported a position in TECH in Q2 2017 and held it in 3 quarters. The position peaked at $4K in Q2 2017. 332 funds tracked by Wall St. Rank hold TECH as of Q1 2018.

  • Winfield Associates reported no remaining Bio-Techne position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 20 Bio-Techne shares in Q1 2018, an estimated $1K.
  • Winfield Associates first reported a position in Bio-Techne in Q2 2017 and held it in 3 quarters.
  • Winfield Associates's Bio-Techne position peaked at $4K in Q2 2017.
  • 332 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.